Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Fig. 2

Tissue PTPRD mutation predicts the efficiency of ICIs in non-squamous NSCLC. a Forest plot of HR of PTPR mutations for PFS in discovery cohort. b, c Progression-free survivals of NSCLC (b) or ns-NSCLC (c) in discovery cohort. d, e Objective responses of NSCLC (d) or ns-NSCLC (e) in discovery cohort. f, g Progression-free survivals of NSCLC (f) or ns-NSCLC (g) in a validation cohort 1. h, i ORR of NSCLC (h) or ns-NSCLC (i) in validation cohort 1. j, k Overall survivals of NSCLC (j) or ns-NSCLC (k) in validation cohort 2

Back to article page